{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:55Z","timestamp":1789471975940,"version":"build-2803163510"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ajo.2024.07.010","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:32:17Z","timestamp":1721435537000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6909-5181","authenticated-orcid":false,"given":"Timothy M.","family":"Janetos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8020-3401","authenticated-orcid":false,"given":"Kunal","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saffiya","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Koreishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ajo.2024.07.010_bib0001","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"10050","key":"10.1016\/j.ajo.2024.07.010_bib0002","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajo.2024.07.010_bib0003","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","article-title":"Success of weekly adalimumab in refractory ocular inflammatory disease","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2024.07.010_bib0004","first-page":"1043","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"7-8","key":"10.1016\/j.ajo.2024.07.010_bib0005","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/09273948.2021.1936565","article-title":"Anti-adalimumab antibodies in patients with non-infectious ocular inflammatory disease: a case series","volume":"30","author":"McKay","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.ajo.2024.07.010_bib0006","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2024.07.010_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","article-title":"Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis","volume":"141","author":"Bellur","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2024.07.010_bib0008","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/art.30209","article-title":"Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study","volume":"63","author":"Korswagen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ajo.2024.07.010_bib0009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","article-title":"Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review","volume":"61","author":"Moustou","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ajo.2024.07.010_bib0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2024.07.010_bib0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942400312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942400312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:03:03Z","timestamp":1737518583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942400312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":11,"alternative-id":["S000293942400312X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.07.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}